Article Sidebar

PDF (Tiếng Việt)
Published: 2025-09-30
Abstract Views: 0
Views PDF (Tiếng Việt): 0
DOI: https://doi.org/10.52852/tcncyh.v194i9.3918
Issue
Vol. 194 No. 9 (2025)
Section
Các bài báo
How to Cite
Hiền, Đàm T., Hà, N. L., Lan, N. T. T., Quỳnh, V. N., Dương, Đỗ N. Q., Lan, Đinh T. T., Châu, N. M., Phương, N. H., Tùng, L. Đình, & Dân, B. V. (2025). 6. An investigation of adverse reactions associated with iodinated contrast media at E Hospital in 2025. Journal of Medical Research, 194(9), 47-55. https://doi.org/10.52852/tcncyh.v194i9.3918

6. An investigation of adverse reactions associated with iodinated contrast media at E Hospital in 2025

Dam Thu Hien, Nguyen Le Ha, Nguyen Thi Thu Lan, Vo Nhu Quynh, Do Ngoc Quy Duong, Dinh Thi Thu Lan, Nguyen Minh Chau, Nguyen Hoang Phuong, Le Dinh Tung, Bui Van Dan

Main Article Content

Abstract

Iodinated contrast media (ICM) are indispensable agents in modern diagnostic imaging. However, their widespread use has been accompanied by a notable increase in the incidence of adverse drug reactions (ADRs). To date, there has been no comprehensive study in Vietnam—particularly at E Hospital- to systematically evaluate the incidence and clinical features of ICM-related ADRs.. This cross-sectional descriptive study was conducted on 2,426 patients who received ICM between February and April 2025. ADRs were monitored during administration and for 24 hours post-exposure. The overall incidence of ICM-related ADRs was 12.2%. Notably, the use of Omnipaque was associated with a higher rate of ADRs (19.8%) compared to Iopamiro (11.0%) . Reported ADRs ranged from mild symptoms such as nausea, fever, and limb paresthesia to grade I and II anaphylactic reactions. A positive correlation was observed between the frequency of ICM exposure and the occurrence of ADRs. Among the two contrast agents evaluated, Iopamiro exhibited a comparatively more favorable safety profile. Nevertheless, further large-scale multicenter investigations are necessary to validate these findings and to more precisely delineate the safety profiles of iodinated contrast agents.

Article Details

Keywords

ICM, ADR, Iopamiro, Omnipaque, anaphylaxis

References

1. Bettmann MA. Frequently asked questions: iodinated contrast agents. Radiographics. 2004; 24(Suppl 1): S3-S10.
2. Bottinor W, Polkampally P, Jovin I. Adverse reactions to iodinated contrast media. Int J Angiol. 2013; 22(3): 149-154. doi:10.1055/s-0033-1348885.
3.Shehadi W H. Adverse reactions to intravascularly administered contrast media. A comprehensive study based on a prospective survey. Am J Roentgenol Radium Ther Nucl Med. 1975; 124(1): 145–152. doi: 10.2214/ajr.124.1.145.
4. Katayama H, Yamaguchi K, Kozuka T, Takashima T, Seez P, Matsuura K. Adverse reactions to ionic and nonionic contrast media. A report from the Japanese Committee on the Safety of Contrast Media. Radiology. 1990; 175(3): 621-628. doi: 10.1148/radiology.175.3.2343107.
5. Bush W H, Swanson D P. Acute reactions to intravascular contrast media: types, risk factors, recognition, and specific treatment. AJR Am J Roentgenol. 1991; 157(6): 1153-1161. doi: 10.2214/ajr.157.6.1950858.
6. Mortelé KJ, Oliva MR, Ondategui S, Ros PR, Silverman SG. Universal use of iso-osmolar iodixanol contrast medium to reduce the risk of adverse reaction: clinical experience in 1400 patients. Radiology. 2005; 237(3): 843–849.
7. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. Am J Cardiol. 2006; 98(6A): 27K–36K.
8. Thomsen HS. Contrast media safety-an update. Eur J Radiol. 2011; 80(1): 77-82.
9. ESUR Contrast Media Safety Committee. ESUR Guidelines on Contrast Media. Version 10.0. 2018.
10. Cochran ST, Bomyea K, Sayre JW. Trends in adverse events after IV administration of contrast media. AJR. 2001; 176:1385-1388.
11. [Guideline] ACR Committee on Drugs and Contrast Media. ACR Manual on Contrast Media 2023. American College of Radiology. Available athttps://www.acr.org/-/media/acr/files/clinical-resources/contrast_media.pdf.
12. Trần Thị Thu Hằng, Nguyễn Hoàng Anh, Nguyễn Quốc Bình. Thuốc cản quang chứa Iod và các phản ứng dị ứng có liên quan. Bản tin cảnh giác dược. 2012 (2): 4-6.
13. Nguyễn Phương Thúy. Phản ứng có hại của thuốc cản quang chứa iod. Bản tin cảnh giác dược. 2018(2): 6-11.
14. An J, Jung H, Kwon OY, et al. Differences in Adverse Reactions Among Iodinated Contrast Media: Analysis of the KAERS Database. J Allergy Clin Immunol Pract. 2019; 7(7): 2205-2211. doi:10.1016/j.jaip.2019.02.035.
15. Baek J, Jeong HW, Heo YJ, et al. Comparison of Safety and Diagnostic Efficacy of Iohexol 240 mgI/mL, Iopamidol 250 mgI/mL, and Iodixanol 270 mgI/mL in Cerebral Angiography: A Prospective, Multicenter Study. Neurointervention. 2024; 19(2): 82-91. doi:10.5469/neuroint.2024.00129.
16. National Center for Biotechnology Information. “PubChem Compound Summary for CID 65492, Iopamidol” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Iopamidol. Accessed 30 June, 2025.
17.National Center for Biotechnology Information. “PubChem Compound Summary for CID 3730, Iohexol” PubChem, https://pubchem.ncbi.nlm.nih.gov/compound/Iohexol. Accessed 30 June, 2025.